Table 1. Basic parameters of patient cohorts.
| age at diagnosis (median, range) | Flt3-ITD (% of positive cases) |
Sex (% of females) |
mutA/D (%) |
Relapsed (%) |
Transplant (%) |
Karyotype aberration | |
|---|---|---|---|---|---|---|---|
| all (N = 398) | 51.0 (19–73) |
42.7 | 54 | 92.6 | 37.5 | 39.2 | 18 of 133 (13.5%) |
| A02+ (N = 164) | 51.5 (21–70) |
41.5 | 54 | 90.4 | 37.2 | 37.0 | 9 of 62 (14.5%) |
| B07+ (N = 81) | 53.0 (19–73) |
30.5 | 56 | 93.4 | 34.2 | 35.5 | 2 of 22 (9.1%) |
| B40+ (N = 25) | 50.5 (30–68) |
48.0 | 60 | 87.5 | 37.5 | 37.5 | 3 of 9 (33.0%) |
| C07+ (N = 134) | 53.0 (19–73) |
45.2 | 53 | 94.5 | 43.4 | 40.9 | 9 of 53 (17.0%) |
| Prague subcohort (N = 94) | 52.5 (24–68) |
45.5 | 60 | 92.6 | 45.7 | 54.8 | 15 of 77 (19.5%) |
| C*07:01+ Prague (N = 20) | 52.0 (24–67) |
50.0 | 65 | 95.0 | 46.7 | 53.6 | 4 of 18 (22.2%) |
Basic characteristics of NPMc+ AML patient cohort and of its subgroups involving patients with selected HLA class I alleles as indicated. The Prague subcohort and its C*07:01-positive subgroup are given in the last two rows. Nucleophosmin mutations were of type A/D (both A and D result in the same protein product) or of type B. Flt3-ITD, internal tandem duplication in FLT3 gene. Karyotype information from cytogenetic analysis was available only in a part of patients and is given as the number of cases with karyotype aberrations as a part of all cases with available results. The percentage of cases with karyotype aberration is given in brackets.